美股A股
StockGist

Tilray Brands, Inc.

TLRYNASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Eur…
$2.43-2.41%
报价 2026-11-13
市值
$271.8M
EV
$488M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -82.6%
$2.43$13.94

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

同行业市值相近 · Drug Manufacturers - Specialty & Generic
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
TLRYTilray Brands, Inc.$271.8M-2.4%–30.1%–––
EOLSEvolus, Inc.$460.7M-3.1%+12.7%65.6%–––
EMBCEmbecta Corp.$366M+0.5%+4.3%59.9%3.3x5.8x1.8xCheap
SNDLSNDL Inc.$335.3M-1.4%–19%–8.8x–
ACBAurora Cannabis Inc.$324.8M-1.0%–-5.9%–––
EBSEmergent BioSolutions Inc.$297.7M-1.7%-20.1%49.4%––4.3x
LFCRLifecore Biomedical, Inc.$243.4M+0.3%+62.7%29.7%–––
CGCCanopy Growth Corporation$237.6M-2.2%–27.4%–––
SIGASIGA Technologies, Inc.$196.9M-5.2%-32.0%––––
同行中位数––+4.3%29.7%3.3x7.3x3.1x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-08-31
Q1 2027
2026-05-31
Q4 2026
2026-02-28
Q3 2026
2025-11-30
Q2 2026
2025-08-31
Q1 2026
2025-05-31
Q4 2025
2025-02-28
Q3 2025
2024-11-30
Q2 2025
Revenue$257.1M$281.7M$206.7M$217.5M$209.5M$224.5M$185.8M$211M
Gross Margin30.1%29.9%26.6%26.4%27.4%30.1%28%29%
Operating Margin-9.4%-1.6%-12.8%-10.2%1%-643.1%-409%-20%
Net Income$-43.1M$-49.6M$-26.6M$-44.9M$-322,000$-1.27B$-789.4M$-85.3M
Diluted EPS-0.32-0.43-0.24-0.41-0-13.01-8.69-0.99
Operating Cash Flow$-16.5M$-37.5M$-22.2M$-11.9M$-1.8M$-19.9M$-5.1M$-56.7M

研究材料